According to the cost-effectiveness bootstrap distributions, the use of TOZ versus ADM, ETC for the management of RA will result in a more significant reduction in the CRP levels but at a higher cost in 99.98% of the bootstrap distributions, as depicted in Fig. 4. Here, CRP is linked to rheumatoid arthritis.